private:neumedicines
|
584852
|
May 30th, 2019 12:00AM
|
Neumedicines Inc.
|
313
|
12.00
|
Open
|
Biotechnology
|
May 30th, 2019 01:44PM
|
May 30th, 2019 01:44PM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
Open
|
|
Open
|
133 North Altadena Drive
|
Pasadena
|
California
|
US
|
91107
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Mar 18th, 2018 12:00AM
|
Neumedicines Inc.
|
299
|
12.00
|
Open
|
Biotechnology
|
Mar 18th, 2018 06:25PM
|
Mar 18th, 2018 06:25PM
|
|
Open
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 17th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 16th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 15th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 14th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 13th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 12th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 11th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|
private:neumedicines
|
584852
|
Feb 10th, 2018 12:00AM
|
Neumedicines Inc.
|
293
|
15.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California.
Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.
|
|
|
|
|
|
|
|
|
|
Neumedicines
|
|
Health Care Equipment & Services
|